osimertinib
astrazeneca
['adaura', 'osimertinib', 'aura ,(-laura)']
1 - most of the oncologist know that most of the control arm of adaura did not get osimertinib on progression ( less than 40 %) and there is no reasonable explanation for the same . ( it was painful to see the explanation given on podium in #asco23 ) 2 - number of oncologist 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists